PROTACs in ER+/HER2- MBC

CME

PROTAC ER Degraders in ER+/HER2- MBC Progressing After Endocrine Therapy: Current Treatment Landscape and Unmet Needs for Patients

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: November 19, 2024

Expiration: April 18, 2025

Erika P. Hamilton
Erika P. Hamilton, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What is the primary mechanism of action of PROTAC ER degraders in the treatment of ER+/HER2- MBC in the post-CDK4/6 inhibitor setting?

2.

Which of the following statements best describes the role of ESR1 mutations in ER+/HER2- MBC for emerging therapies such as PROTAC ER degraders?